Hannah Z R McConkey1, Michael Marber1, Amedeo Chiribiri1, Philippe Pibarot2, Simon R Redwood1, Bernard D Prendergast1. 1. Cardiovascular Division, King's College London British Heart Foundation Centre of Excellence, The Rayne Institute, St. Thomas' Hospital Campus, London, United Kingdom (H.Z.R.M., M.M., A.C., S.R.R., B.D.P.). 2. Department of Medicine, Institut Universitaire de Cardiologie et de Pneumologie de Québec/Québec Heart and Lung Institute, Laval University, Québec, Canada (P.P.).
Abstract
Aortic stenosis is a heterogeneous disorder. Variations in the pathological and physiological responses to pressure overload are incompletely understood and generate a range of flow and pressure gradient patterns, which ultimately cause varying microvascular effects. The impact of cardiac-coronary coupling depends on these pressure and flow effects. In this article, we explore important concepts concerning cardiac physiology and the coronary microcirculation in aortic stenosis and their impact on myocardial remodeling, aortic valve flow patterns, and clinical progression.
Aortic stenosis is a heterogeneous disorder. Variations in the pathological and physiological responses to pressure overload are incompletely understood and generate a range of flow and pressure gradient patterns, which ultimately cause varying microvascular effects. The impact of cardiac-coronary coupling depends on these pressure and flow effects. In this article, we explore important concepts concerning cardiac physiology and the coronary microcirculation in aortic stenosis and their impact on myocardial remodeling, aortic valve flow patterns, and clinical progression.
“There is a form of cardiac lesion, not infrequent in occurrence, which has a clinical picture so characteristic that it deserves more frequent recognition than it commonly receives.”Henry A Christian, 18th July 1931[1]Severe symptomatic aortic stenosis (AS) has a bleak prognosis[2,3] and no medical treatment exists. As the population ages, the clinical importance and burden of AS are increasing, yet its diagnosis and management are multifaceted, especially in the era of percutaneous interventions. AS is characterized by progressive valve narrowing, which clinically manifests as dyspnea, syncope, and angina despite normal coronary arteries, and patients have a truncated life span of around 2 years without intervention. However, symptomatology is subjective and confounded by comorbidities (particularly in the aging population), and assessment of transvalvular pressures is heavily flow dependent. The clinician is therefore faced with the challenge of evaluating discordant parameters and balancing the potential risks and benefits of valve intervention.In 1616, William Harvey was the first to propose that blood circulates because of pulsatile cardiac force.[4] Interactions between the cardiac cycle and coronary circulatory flow were described in 1696 by Scaramucci who suggested that the coronary vasculature is filled in diastole and squeezed empty during systole.[5] Cardiac-coronary coupling is pertinent in AS because alterations to the coronary microcirculation are synonymous with the pathophysiology of progressive disease. Disruption to the coronary circulation by ventricular hypertrophy, high left ventricular pressure, low coronary perfusion pressure, and extravascular forces (among many other factors) reduce physiological reserve. The ominous symptom of angina correlates with impaired myocardial perfusion reserve and is strongly associated with increased ventricular mass index.[6] The fact that clinical symptoms occur at the end of the ischemic cascade (whereas perfusion abnormalities can be detected earlier) places great expectation on the physiological evaluation of AS.[7]Patients with aortic stenosis and an aortic valve area (AVA) < 1 cm2 exhibit distinct pathophysiological responses to pressure overload. The ventricle remodels in response to pressure overload in different ways, generating a range of flow and pressure gradient patterns which ultimately cause varying microvascular effects. Detailed understanding of the pressure-flow relationship in this setting is important in fully understanding a patient’s symptoms and the complex relationship between disrupted coronary flow, left ventricular mechanics, and surrogate markers of ischemia.
Cardiac-Coronary Coupling in Health
Normal resting coronary blood flow comprises around 4% of total cardiac output,[8] and both oxygen extraction and the myocardial metabolic rate are high when compared with skeletal muscle. During the cardiac cycle, cardiac contraction cyclically increases intramural tissue and microvascular pressures to impede systolic flow. This contraction induces greater subendocardial resistance and blood displacement in comparison with the subepicardium.[9,10] Once the aortic valve closes and left ventricular (LV) relaxation ensues, the coronary vessels embedded in the myocardium recoil and blood flow accelerates. Coronary flow is dictated by this effect of cardiac contraction—the intramyocardial pump—which pushes blood backward and draws it in during systole and diastole, respectively,[11] (Figure 1)[12,13] but is also modulated by aortic and LV pressure, and inotropic state.
The coronary vascular bed acts as the primary gatekeeper to myocardial blood supply. Resting myocardial blood flow (MBF) is the greatest in the subendocardium (endocardial/epicardial flow ratio 1.29–1.35[11,31]), but subepicardial MBF is augmented during adenosine-induced hyperemia to a greater extent. During systole, there is significant subendocardial underperfusion because of the aforementioned physical determinants (transmural perfusion endocardial to epicardial ratio 0.38[11]). After a period of ischemia, reactive hyperemia is earliest in the subepicardium,[9] and this delayed subendocardial response is thought to be because of sluggish reopening of the coronary vasculature embedded in ischemic, poorly compliant myocardium.Among many other mechanisms, the gradient in coronary perfusion pressure (difference between aortic and LV end diastolic pressure) facilitates coronary perfusion, and flow is determined by the product of the net velocity-time integral and cross-sectional arterial area (Q=VA). The largest cross-sectional area exists in the microvasculature where reduced velocity allows adequate time for capillary bed gas transfer. In normal hearts, aortic and LV pressures are coupled during systolic ejection and higher perfusion pressure gradients enable coronary perfusion during diastole. There is a nonlinear connection between cross-sectional area and transmural pressure because vascular tone is influenced by metabolic/neurohormonal mediators and physical forces. According to Ohm’s law, flow through a vascular bed is equal to the perfusion pressure gradient divided by vessel resistance, 8ηl/πr4 (Hagen-Poiseuille equation, where η is blood viscosity, l is vessel length, and r is vessel radius). Microvascular resistance is therefore primarily determined by lumen diameter and vasodilatation is the principle means of microcirculatory autoregulation.During maximal coronary vasodilatation, coronary flow depends on the relative duration of diastole.[32] This diastolic time fraction (the length of diastole/length of cardiac cycle) has an inverse relationship with heart rate and is also determined by other modulators of systolic duration (such as altered myocyte contraction). Decreased coronary perfusion pressure induces an increase in diastolic time fraction, which in turn reduces the duration of intramyocardial vessel compression.
Coronary Wave Intensity Analysis
Studies of wave intensity analysis have identified 4 main coronary waves within the cardiac cycle in health and disease[33] (Figure 3).
Figure 3.
The 4 dominant coronary waves during the cardiac cycle in relation to hemodynamic indices (not to scale). BCW indicates backward compression wave; BEW, backward expansion wave; FCW, forward compression wave; and FEW, forward expansion wave.
The 4 dominant coronary waves during the cardiac cycle in relation to hemodynamic indices (not to scale). BCW indicates backward compression wave; BEW, backward expansion wave; FCW, forward compression wave; and FEW, forward expansion wave.Quantification of net wave intensity through the product of changes in pressure and flow velocity makes it possible to segregate components of coronary flow into forward or backward traveling waves from the aorta or microcirculation, and those caused by suction (expansion) or compression—blood can be pushed into or pulled out of the coronary circulation. Flow from the coronary circulation to the myocardium is largely determined by the prominent backward expansion wave (BEW), originating at the onset of LV relaxation. The decelerating backward compression wave and forward expansion wave impede coronary flow, while the BEW and forward compression wave are accelerating waves. Information concerning the size, direction, and duration of coronary waves throughout the cardiac cycle has helped us understand coronary flow in normal hearts, in AS,[19] and transcatheter aortic valve implantation (TAVI),[34,35] hypertrophic cardiomyopathy[36] and several other settings.[33,37-42]
Cardiac-Coronary Coupling in AS
The pathophysiology of calcific degenerative AS has 2 distinct phases: initiation and propagation.[43] The former overlaps with the development of atherosclerosis, centered around endothelial disruption and activation of inflammatory responses. Progressive AS induces left ventricular hypertrophy (LVH) to increase contractile force and reduce wall stress[44] in response to progressive and eventually insurmountable afterload. Compressive forces resulting from rising intracavitary pressure determine coronary perfusion pressure and limit coronary circulatory response to increased myocardial demand—an association related to the extent of LVH.[45] Oxygen requirements increase while perfusion through the small perforating coronary network is compromised by fixed elevated systolic wall stress[46,47] and reduced relative capillary density,[48,49] creating supply-demand mismatch. These structural changes of vascular rarefaction, compressive forces, and perivascular fibrosis and functional changes, such as reduced diastolic perfusion time (DPT, defined as [RR interval]−[S1-S2 interval]×heart rate) and endothelial and smooth muscle dysfunction, all exert adverse effects.Preferential coronary flow shifts from the endocardium to epicardium resulting in a significant decrease in subendocardial (but not subepicardial) MBF.[50] This reversal of normal endocardial-epicardial blood flow ratio[51] at rest is fundamental to the pathophysiology of AS, resulting in subendocardial ischemia,[52] apoptosis,[47] and fibrosis—clinically manifest as angina despite normal epicardial coronary arteries. Noninvasive detection of this shift in resting endocardial-epicardial ratio could be used to guide timing of valve intervention.Severe AS exhibits an array of flow parameters, but there is significant LV outflow tract obstruction in all forms, typically accompanied by LVH,[53] which may cause dynamic obstruction in late systole with systolic anterior motion of the mitral valve. Unlike hypertrophic cardiomyopathy, where there is a strong linear relationship between peak-to-peak gradient and peak instantaneous gradients, significant scatter exists in AS patients.[54]One study demonstrated that severity of AS and parameters of LV workload (but not LVH or diastolic indices) have important roles in determining coronary flow reserve (CFR).[55] Another study, however, correlated impaired perfusion reserve with valve stenosis, myocardial fibrosis, and strongly with LVH.[45] Cardiac amyloid is common in this population and may confound results.There are strong similarities in the pathogenic manifestations of AS and hypertension, that is, interstitial and perivascular fibrosis, cardiomyocyte hypertrophy, reduced DPT, increased diastolic filling pressure (compressing the endocardium) and diastolic dysfunction, capillary rarefaction,[51] and arteriolar remodeling.[56] However, key differences exist. The BEW is the most important contributor to coronary blood flow and a measure of microcirculatory function—it is increased at rest in AS[34,35] but reduced in isolated LVH,[33] probably as a result of lower wall stress and slower isovolumetric LV relaxation (dP/dtmin). Furthermore, there is a direct relationship between systolic coronary velocity and systolic perfusion pressure in hypertensivepatients with no AS—extravascular compressive forces which normally impede systolic coronary flow may be overcome in the setting of higher perfusion pressure.[57]After TAVI or surgical aortic valve replacement, there is restoration of myocardial perfusion, oxygenation, energetics, and contractility, accompanied by improved microcirculatory function as a result of the relief of mechanical obstruction and wall stress, and eventual LVH regression.[58,59] Indexed stroke volume drops sharply (41±8 to 33±10 mL/m2; P<0.001) as a result of increased systemic vascular resistance (P<0.0001), despite no clear difference in global afterload measured by valvulo-arterial impedance (Zva).[60] Hyperemic microvascular resistance (hMR) decreases after TAVI, independent of resting hemodynamics.[61] Remaining hypertrophy continues to influence coronary physiology with improved (but not normalized) CFR.
Disrupted Coronary Flow in AS
Microcirculatory autoregulation induces vasodilation to minimize microvascular resistance and increase total resting MBF, resulting in reduced CFR[62,63] and MPR[64] because of paired inability to further vasodilate (Figure 4[65]). Low coronary perfusion pressure,[66] extravascular compressive forces,[67] and reduced DPT[46,56,61] all seem to play a role. Reduced DPT because of prolonged systole in AS supports the maldistribution theory.[68]
Factors implicated in disrupted coronary flow and reduced coronary flow reserve in aortic stenosis. Compensatory mechanisms fail because of structural and mechanical effects on the ventricle and coronary circulation. There is reduced physiological reserve as a result of inadequate myocardial oxygen supply and increased oxygen demand. BEW indicates backward expansion wave; CBF, coronary blood flow; DPT, diastolic perfusion time; and VTI, velocity-time integral.
Factors implicated in disrupted coronary flow and reduced coronary flow reserve in aortic stenosis. Compensatory mechanisms fail because of structural and mechanical effects on the ventricle and coronary circulation. There is reduced physiological reserve as a result of inadequate myocardial oxygen supply and increased oxygen demand. BEW indicates backward expansion wave; CBF, coronary blood flow; DPT, diastolic perfusion time; and VTI, velocity-time integral.Lumley et al[19] found that perfusion efficiency during exercise in patients with AS was reduced when compared with normal patients, as a result of augmented early systolic deceleration waves (backward compression wave) and attenuated rise in systolic acceleration waves (forward compression wave). Importantly, further assessment found that AS patients and those with normal hearts are able to reduce microvascular resistance to the same extent.[19] Decreased hMR after TAVI independent of resting hemodynamics has also been demonstrated in patients with severe AS (not differentiated into flow or pressure gradient status).[61] Clearly, both intra- and extra-myocardial pressures dictate coronary supply and a combination of factors is likely to be responsible for the distortion of coronary flow and impaired CFR in AS.
Aortic Valve Flow and Pressure Gradients
The adaptive compensatory response to AS ultimately become maladaptive and results in cardiac decompensation, yet there are several guises with distinct anatomic and physiological characteristics (Figures 6 and 7).[78] Normal-flow high-gradient AS usually provokes concentric hypertrophy, whereas paradoxical low-flow low-gradient (pLFLG) AS patients demonstrate concentric remodeling.[79]
Figure 6.
Classification of aortic stenosis according to flow (low-flow <35 mL/m Low-flow low-gradient can be further subdivided into classical and paradoxical according to the presence or absence of impaired left ventricular function. LFHG indicates low flow-high gradient; LFLG, low flow-low gradient; NFHG, normal flow-high gradient; and NFLG, normal flow-low gradient.
The complex collagen weave is responsible for much of the ventricle’s passive diastolic stiffness,[118] and remodeling in response to pressure overload causes fibroblast proliferation and collagen I accumulation.[119] Myocardial collagen deposition is a common end point of many pathologies and accompanies advanced aging.[120] Myocardial hypertrophy is detrimental to overall survival[121-123] and correlates with fibrosis, impaired longitudinal shortening, and worsening diastolic function. This fibrosis associated with AS[124-127] is a crucial determinant of cardiac dysfunction and prognosis,[116,124,125,128,129] and replacement fibrosis may be the result of myocyte apoptosis accounting for progression to heart failure.[130] Interstitial, subendocardial, and mid-wall patterns of fibrosis have been demonstrated in patients with AS and normal coronary arteries.[85,116,117,123,131-137]While endomyocardial biopsy is the gold standard for confirming fibrosis,[138] cardiac magnetic resonance imaging has been widely used in its detection, either using T1 mapping to calculate extracellular volume fraction or late gadolinium enhancement. Extracellular volume fraction can detect extracellular volume expansion with diffuse fibrosis, whereas late gadolinium enhancement only identifies replacement fibrosis.[139]Patients with pLFLG AS typically have more profound impairment of LV longitudinal function[98,114,140-142] and more florid myocardial fibrosis, predominantly located in the subendocardium.[85] In comparison to circumferential fibers located in the mid-wall, longitudinal subendocardial fibers (responsible for long-axis function)[143-146] are particularly vulnerable to microvascular ischemia and wall stress.[85,131] Impaired longitudinal function as a consequence of subendocardial injury, small LV cavity size, and increased wall thickness lead to reduced stroke volume and lower flow-dependent valve gradients.[147] Reduced stroke volume is primarily because of deficient LV filling (rather than emptying),[95] and preserved LVEF should not be construed as normal systolic function. Consistent with this theme, a recent study demonstrated that indexed AVA, female sex, an abnormal exercise ECG and myocardial perfusion reserve (but not valve gradients or LV function) were independent predictors of event rates in moderate-severe AS.[148]This distinct remodeling may be explained by decreased cardiac reserve resulting from chronic exposure to high afterload, eventually exceeding the limit of compensatory mechanisms with resulting LV impairment and reduced cardiac output.[86] It is also possible that these patients have a coexisting or secondary heart failure syndrome, akin to heart failure with preserved ejection fraction,[149] the cause of which is complex and poorly understood. Importantly, these 2 pathologies (which are both relatively common in older age) are not mutually exclusive and exhibit significant similarities, including impaired LV relaxation and microvascular abnormalities.[46,73,150-153] Indeed, galactin-3, a novel marker of myocardial fibrosis, has prognostic value in heart failure with reduced or preserved ejection fraction[154,155] and is associated with adverse outcomes after TAVI[156]—despite the lack of any association with AS severity.[157] Patients with elevated galactin-3 before TAVI have lower valve gradients and reduced LVEF (although data were not divided into AS cohorts).[156] Similarly, 1 study revealed that low flow (but not low LVEF or low gradient) is an independent predictor of early and late mortality after TAVI in high-risk AS patients.[100] Comparable to patients with heart failure, LVEF does not correlate with outcomes.Equally, the peril of low flow does not correlate with aortic valve calcification. There is less aortic valve calcification but higher global afterload in pLFLG than other types of AS,[80] suggesting a coexistent ventricular disease entity that may explain why these patients have reduced survival benefit after valve intervention than other subgroups. This would support the theory that pLFLG AS is not end-stage normal-flow high-gradient AS[158] but a distinct and separate entity.[159-161] Furthermore, the concept of pLFLG AS as a transition stage from nonsevere to severe[80] is undermined by a preponderance of myocardial injury and adverse outcomes.
Clinical Implications of Impaired Coronary Flow
Reduced capacity to augment myocardial oxygenation in response to stress is a physiological hallmark of AS and manifest by angina, dyspnea, and syncope. Up to 40% of patients with AS experience angina despite normal coronary arteries[162] and are at increased risk of sudden death.[163] These patients have reduced MBF, impaired CFR, and increased apoptosis[47] and are more likely to have impaired reserve[6,162] and diminished exercise capacity.[64] One study found that low CFR was the only independent predictor of future cardiovascular events in AS patients.[164] Exertion accentuates the imbalance between supply and demand, and rising LV end diastolic pressure blunts the pressure gradient required to achieve adequate coronary perfusion. Any rise in LV end diastolic pressure or fall in AVA has a deleterious effect on coronary supply,[35,46] and there is a strong association between ventricular load (measured by LV rate-pressure product) and decreased CFR, particularly affecting the subendocardium.[46] Stuttering ischemia yields subclinical LV dysfunction and apoptosis, which is linked with myocardial fibrosis[165]—an independent predictor of mortality.[116]Biomarkers have an emerging role in the assessment of asymptomatic AS.[166] High-sensitivity troponin I correlates with LVH, fibrosis, and clinical event rates,[134] while cardiac myosin-binding protein C correlates closely with LV mass, fibrosis, and all-cause mortality (but not valve gradient).[167] BNP (NT-pro B-natriuretic peptide) levels are significantly higher in paradoxical and classical low-flow low-gradient AS,[85] and correlate with CFR ≤2.5 and parameters of diastolic function[168]—use of BNP in asymptomatic AS is endorsed by recent European guidelines.[112]
Conclusions
Patients with AS host a caustic environment where impaired microvascular responses are compounded by high wall stress and hemodynamic load; those with angina (and impaired CFR) are at increased risk of sudden death. Progression of AS is characterized by discrepancies between blood supply and metabolic demand. There is an array of abnormalities in myocardial remodeling, stroke volume, pressure gradients, and disordered coronary flow, which contribute to the signatures that determine varying AS phenotypes. These distinctions, which correlate with clinical outcomes, should prompt a directive path of physiological research. All patients with AS are not equal and the optimal timing and modality of treatment might differ according to phenotype. Relying on peak velocity to determine severity is now obsolete. Timing of intervention is crucial in avoiding irreversible myocardial fibrosis and a burnt out ventricle. Assessment of microcirculatory function may hold the key.
Sources of Funding
H. McConkey is supported by a Clinical Research Training Fellowship grant from the British Heart Foundation (FS/16/51/32365).
Disclosures
None.
Table.
Classification of Coronary Microvascular Dysfunction[66]
Authors: B Villari; S E Campbell; O M Hess; G Mall; G Vassalli; K T Weber; H P Krayenbuehl Journal: J Am Coll Cardiol Date: 1993-11-01 Impact factor: 24.094
Authors: Kaleab N Asrress; Rupert Williams; Timothy Lockie; Muhammed Z Khawaja; Kalpa De Silva; Matthew Lumley; Tiffany Patterson; Satpal Arri; Sana Ihsan; Howard Ellis; Antoine Guilcher; Brian Clapp; Philip J Chowienczyk; Sven Plein; Divaka Perera; Michael S Marber; Simon R Redwood Journal: Circulation Date: 2017-05-03 Impact factor: 29.690
Authors: Yousif Ahmad; Matthias Götberg; Christopher Cook; James P Howard; Iqbal Malik; Ghada Mikhail; Angela Frame; Ricardo Petraco; Christopher Rajkumar; Ozan Demir; Juan F Iglesias; Ravinay Bhindi; Sasha Koul; Nearchos Hadjiloizou; Robert Gerber; Punit Ramrakha; Neil Ruparelia; Nilesh Sutaria; Gajen Kanaganayagam; Ben Ariff; Michael Fertleman; Jon Anderson; Andrew Chukwuemeka; Darrel Francis; Jamil Mayet; Patrick Serruys; Justin Davies; Sayan Sen Journal: JACC Cardiovasc Interv Date: 2018-08-25 Impact factor: 11.195
Authors: Dorota Długosz; Andrzej Surdacki; Barbara Zawiślak; Stanisław Bartuś; Bernadeta Chyrchel Journal: J Clin Med Date: 2022-05-19 Impact factor: 4.964